Role of the L-arginine/nitric oxide system in the action of nebivolol;Bedeutung des L-arginin/NO-systems für die wirkung von nebivolol

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 45, 2006, Pages 2545-2550

  Brodde, Otto Erich ^a,b   Philipp, T ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Institut fur Pathophysiologie   (Germany)

Author keywords

L arginine nitric oxide system; Nebivolol

Indexed keywords

ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; METOPROLOL; NADOLOL; NEBIVOLOL; NITRIC OXIDE; PROPRANOLOL DERIVATIVE; TIMOLOL;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HYPERTENSION; REVIEW; RISK FACTOR; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ARGININE; BENZOPYRANS; CORONARY DISEASE; ETHANOLAMINES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; NITRIC OXIDE; RECEPTORS, ADRENERGIC, BETA; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 33751543440     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955047     Document Type: Review

References (44)

1. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948; 153: 586-600
2. Black JW, Crowther AF, Shanks RC, Smith LH, Dornhorst AC. A new adrenergic beta-receptor antagonist. Lancet 1964; 1: 1080-1081
3. Bode-Böger SM. Einfluss von L-Arginin auf die Arterioskleorseentwicklung: Was ist therapeutisch gesichert? Dtsch Med Wochenschr 2005; 130: 593-598
4. Böger RH. Assymmetrisches Dimethylarginin (ADMA) als kardiovaskulärer Risikofaktor. Dtsch Med Wochenschr 2004; 129: 820-824
5. Böger RH, Bode-Böger S. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001; 41: 79-99
6. Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204
7. Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49: 430-439
8. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569
9. Brodde O-E. Die Bedeutung von L-Arginin und NO für die Behandlung der endothelialen Dysfunktion. Nieren- und Hochdruckkrankheiten 2004; 33: 679-686
10. Brodde O-E, Kroemer HK. Drug-drug interactions of β-adrenoceptor blockers. Arzneim-Forsch/Drug Res 2003; 53: 814-822
11. Brodde O-E, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51: 651-689
12. Broeders MAW, Doevendans PA, Bekkers BCAM et al. Nebivolol: a third-generation β-blocker that augments vascular nitric oxide release. Circulation 2000; 102: 677-684
13. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
14. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-Arginine/NO-dependent mechanism. J Pharmacol ExpTher 1995; 274: 1067-1071
15. Dawes M, Brett SE, Chowienczyk PJ, Mant TCK, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-463
16. 3- adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 2005; 112: 1198-1205
17. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholestolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550
18. Flather MD, Shibata MC, Coats AJ et al.: SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225
19. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999; 19: 235-251
20. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells. Nature 1980; 288: 373-376
21. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-969
22. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule in vascular biology. Biosci Rep 1999; 19: 51-71
23. Ignarro LJ. Experimental evidence of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation β-blocker. Blood Press 2004(Suppl 113: 2-16
24. Ignarro LJ, Buga GM, Wei LH et al. Role of the arginie-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Si USA 2001; 98: 4202-4208
25. Ignarro LJ, Sisodia M, Trinh K et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002; 7: 83-90
26. Kakoki M, Hirata Y, Hayakawa H et al. Effects of vasodilatatory β-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999(part II) 33: 467-471
27. Kizer JR, Dahlöf B, Kjeldsen SE et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 46-52
28. Lands AM et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214: 597-598
29. Li H, Wallerath T, Münzel T, Förstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002; 7: 149-164
30. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553
31. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007
32. Mollnau H, Schulz E, Daiber A et al. Nebivolol prevents vascular NOS: III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23: 615-621
33. Moncada S, Higgs A. The L-arginine-nitric oxide pathay. N Engl J Med 1993; 329: 2002-2012
34. Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci Rep 1999; 19: 133-154
35. Packer M, Bristow MR, Cohn JN et al. U.S. Carvedilol heart failure study group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355
36. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12
37. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 1977; 77: 1-124
38. Sydow K, Münzel T. ADMA and oxidative stress. Artheroclerosis Suppl 2003; 4: 41-51
39. Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003; 100: 215-234
40. Vallance P, Leone A et at. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-575
41. Van Bortel LMAB, de Hoon JNJM et al. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 1997; 51: 379-384
42. 1- adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-563
43. Van Nueten L, De Cree J. Nebivolol. Comparison of the effects of d1-Nebivolol, d-Nebivolol, I-Nebivolol, Atenolol, and Placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 1998; 12: 339-344
44. Waagstein F, Bristow MR, et al. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446